Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions
- 16 February 2016
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (12) , 5563-5586
Abstract
Heat shock protein 90 (Hsp90) is a ubiquitous chaperone of all of the oncogenic tyrosine kinases. Many Hsp90 inhibitors, alone or in combination, have shown significant antitumor efficacy against the kinase-positive naïve and mutant models. However, clinical trials of these inhibitors are unsuccessful due to insufficient clinical benefits and nonoptimal safety profiles. Recently, much progress has been reported on the Hsp90–cochaperone–client complex, which will undoubtedly assist in the understanding of the interactions between Hsp90 and its clients. Meanwhile, Hsp90 inhibitors have shown promise against patients’ resistance caused by early generation tyrosine kinase inhibitors (TKIs), and at least 13 Hsp90 inhibitors are being reevaluated in the clinic. In this regard, the objectives of the current perspective are to summarize the structure and function of the Hsp90–cochaperone–client complex, to analyze the structural and functional insights into the Hsp90–client interactions to address several existing unresolved problems with Hsp90 inhibitors, and to highlight the preclinical and clinical studies of Hsp90 inhibitors as an effective treatment against resistance to tyrosine kinase inhibitors.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2015CB910603)
- National Natural Science Foundation of China (81125021, 81321092, 81373277, 81430080, 81473243)
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CASIMM0120154002/2002)
This publication has 155 references indexed in Scilit:
- Development of a Grp94 inhibitorJournal of the American Chemical Society, 2012
- Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012
- A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaGynecologic Oncology, 2012
- Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsInvestigational New Drugs, 2012
- A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumorsCancer Chemotherapy and Pharmacology, 2011
- Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate CancerUrology, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapyFEBS Letters, 2010
- Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsInvestigational New Drugs, 2010
- Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignanciesEuropean Journal of Cancer, 2010